Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Ketamine in Neuropathic Cancer Pain
NCT01951911Phase 3Withdrawn
- Sponsor
- Haukeland University Hospital
- Start
- Sep 2013
- Primary completion
- Oct 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in cancer pain comparing Ketamine with Placebo (2 arms). Primary endpoint: Change in pain intensity compared to baseline at 5 days. Planned start Sep 2013; status: withdrawn.
02
Drugs
ketamine
03
Conditions
cancer pain
Beyond the preview
Go deeper on NCT01951911.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01951911.